Your browser doesn't support javascript.
loading
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer, Nurit; Giladi, Nir; Gurevich, Tanya; Bar-Shira, Anat; Gana-Weisz, Mali; Glinka, Tal; Goldstein, Orly; Kestenbaum, Meir; Cedarbaum, Jesse M; Mabrouk, Omar S; Fraser, Kyle B; Shirvan, Julia C; Orr-Urtreger, Avi; Mirelman, Anat; Thaler, Avner.
Afiliación
  • Omer N; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Giladi N; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Gurevich T; Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Bar-Shira A; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Gana-Weisz M; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Glinka T; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
  • Goldstein O; Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Kestenbaum M; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Cedarbaum JM; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
  • Mabrouk OS; Genetic Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Fraser KB; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Shirvan JC; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Orr-Urtreger A; Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
  • Mirelman A; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Thaler A; Neurology Department, Meir Medical Center, Kfar-Saba, Israel.
Mov Disord ; 37(1): 190-195, 2022 01.
Article en En | MEDLINE | ID: mdl-34550621
ABSTRACT

BACKGROUND:

Mutations in the GBA gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), are risk factors for Parkinson's disease (PD).

OBJECTIVE:

To explore the association between GCase activity, PD phenotype, and probability for prodromal PD among carriers of mutations in the GBA and LRRK2 genes.

METHODS:

Participants were genotyped for the G2019S-LRRK2 and nine GBA mutations common in Ashkenazi Jews. Performance-based measures enabling the calculation of the Movement Disorder Society (MDS) prodromal probability score were collected.

RESULTS:

One hundred and seventy PD patients (102 GBA-PD, 38 LRRK2-PD, and 30 idiopathic PD) and 221 non-manifesting carriers (NMC) (129 GBA-NMC, 45 LRRK2-NMC, 15 GBA-LRRK2-NMC, and 32 healthy controls) participated in this study. GCase activity was lower among GBA-PD (3.15 ± 0.85 µmol/L/h), GBA-NMC (3.23 ± 0.91 µmol/L/h), and GBA-LRRK2-NMC (3.20 ± 0.93 µmol/L/h) compared to the other groups of participants, with no correlation to clinical phenotype.

CONCLUSIONS:

Low GCase activity does not explain the clinical phenotype or risk for prodromal PD in this cohort. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Glucosilceramidasa Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Glucosilceramidasa Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Israel